BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» Dualyx completes series A financing to advance Treg therapies for autoimmune diseases
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immune
Dualyx completes series A financing to advance Treg therapies for autoimmune diseases
May 15, 2023
No Comments
Dualyx NV has completed a €40 million (US$44 million) series A financing, allowing the company to advance its lead autoimmune program, DT-001, as well as its pipeline of regulatory T-cell (Treg) candidates.
BioWorld Science
Financings
Immune
Series A